Novo Nordisk shareholders are suing the drugmaker over its experimental obesity treatment CagriSema, alleging the company misled investors about a key clinical trial before releasing disappointing results that wiped billions of dollars off its market value. A federal judge on Tuesday allowed parts of that lawsuit to move forward, finding that investors had plausibly alleged…
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The market share of India’s most popular weight‑loss drugmaker, Eli Lilly, slipped in March, while rival Novo Nordisk held steady even as Indian generic drugmakers flooded the market with lower‑priced copies. Eli Lilly’s Indian market share in the GLP‑1 category of…
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Novo Nordisk, a landmark decision that health experts say could…
